MCID: LYM118
MIFTS: 70

Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Lymphoma

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 12 76 29 55 6 43 44 15 73
Lymphoid Neoplasm 55 73
Lymphoid Cancers 73
Lymphoid Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060058
ICD10 33 C85.9
MeSH 44 D008223
NCIt 50 C3208 C7065
SNOMED-CT 68 21964009

Summaries for Lymphoma

MedlinePlus : 43 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to follicular lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with Lymphoma is TCL6 (T Cell Leukemia/Lymphoma 6), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Pathways in cancer. The drugs Adcetris and Arranon have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 76 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphoma

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1742)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 34.5 BCL10 BCL2 BCL6 CCND1 MYC
2 lymphoma, mucosa-associated lymphoid type 34.3 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
3 diffuse large b-cell lymphoma 34.3 BCL6 MALT1 MYC
4 lymphoma, hodgkin, classic 34.3 ALK BCL6 PVT1
5 peripheral t-cell lymphoma 34.2 ALK BCL6 TCL1A
6 follicular lymphoma 1 34.1 BCL10 BCL2 BCL6
7 gastric lymphoma 34.1 BAX BCL10 BCL2 BCL6
8 primary effusion lymphoma 34.1 BCL6 MALT1 MYC TCL1A
9 burkitt lymphoma 34.0 BAX BCL2 BCL6 BCL7A CXCR5 MYC
10 lymphoma, non-hodgkin, familial 34.0 ALK ATM BAX BCL10 BCL2 BCL6
11 mantle cell lymphoma 33.9 ATM BCL2 BCL6 CCND1 GAS5 MALT1
12 marginal zone b-cell lymphoma 33.9 BCL10 BCL2 BCL6 CCND1 MALT1
13 lymphoma, small cleaved-cell, diffuse 33.8 BCL2 CCND1
14 primary mediastinal large b-cell lymphoma 33.8 BCL2 BCL6 MYC
15 alk-negative anaplastic large cell lymphoma 33.7 ALK BAX BCL2 MYC
16 nodal marginal zone b-cell lymphoma 33.7 BCL2 BCL6 MALT1
17 primary cutaneous marginal zone b-cell lymphoma 33.6 BCL10 MALT1
18 intravascular large b-cell lymphoma 33.6 BCL2 BCL6
19 lung lymphoma 33.6 ALK BCL6 MALT1
20 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 33.6 BCL6 CXCR5
21 diffuse large b-cell lymphoma of the central nervous system 33.5 BCL2 MYC
22 b-cell lymphomas 33.4 BAX BCL10 BCL2 BCL6 CCND1 GAS5
23 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 33.2 BCL2 BCL6 MYC
24 acute t cell leukemia 32.6 BAX BCL10 BCL11B TCL6
25 precursor t-cell acute lymphoblastic leukemia 32.5 BAX BCL10 MYC TCL1A
26 leukemia, chronic lymphocytic 32.4 ATM BAX BCL10 BCL2 BCL6 CCND1
27 lymphocytic leukemia 31.3 ATM BCL2 DLEU2 MYC
28 t-cell leukemia 31.3 ATM BCL11B GAS5 MYC TCL1A TCL6
29 autoimmune lymphoproliferative syndrome, type v 30.9 ALK BCL2 BCL6 TCL1A
30 myeloma, multiple 30.5 CCND1 GAS5 MYC PVT1
31 intestinal disease 30.4 BCL6 CCND1 MYC
32 prolymphocytic leukemia 30.3 ATM CCND1 MYC TCL1A
33 lung cancer 30.1 ALK ATM BAX BCL2 CCND1 GAS5
34 t-cell prolymphocytic leukemia 30.1 ATM MYC TCL1A
35 extramedullary plasmacytoma 30.0 BCL2 CCND1
36 chromosomal triplication 29.9 BCL6 MALT1
37 glioma 29.8 BAX BCL2 CCND1 GAS5 PVT1
38 acute promyelocytic leukemia 29.7 BAX BCL2 MYC PVT1
39 nasopharyngeal carcinoma 29.7 BCL2 CCND1 GAS5 MYC PVT1
40 li-fraumeni syndrome 29.6 ATM BAX BCL2
41 gastric cancer 29.5 BAX BCL2 CCND1 GAS5 MYC PVT1
42 suppressor of tumorigenicity 3 29.5 BAX BCL2 MYC
43 ovarian cancer 29.5 ATM BAX BCL2 CCND1 GAS5 MYC
44 endometrial cancer 29.4 BAX BCL2 CCND1 GAS5 MYC
45 cervical cancer 29.3 BAX BCL2 CCND1 GAS5 MYC PVT1
46 synchronous bilateral breast carcinoma 29.1 ATM CCND1
47 colorectal cancer 28.9 BAX BCL10 BCL2 CCND1 GAS5 MYC
48 bladder urothelial carcinoma 28.9 BAX CCND1 GAS5 PVT1
49 bladder cancer 28.9 CCND1 GAS5 MYC PVT1 SNHG5
50 adamantinoma of long bones 28.8 BAX BCL2 CCND1 GAS5 MYC PVT1

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma

Symptoms & Phenotypes for Lymphoma

GenomeRNAi Phenotypes related to Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 ATM BAX BCL10 BCL2 MALT1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 ATM BAX BCL10 BCL2 CCND1 MALT1

MGI Mouse Phenotypes related to Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ATM BAX BCL10 BCL11A BCL11B BCL2
2 endocrine/exocrine gland MP:0005379 10.02 ALK ATM BAX BCL10 BCL11A BCL11B
3 hematopoietic system MP:0005397 10 ATM BAX BCL10 BCL11A BCL11B BCL2
4 immune system MP:0005387 9.9 ATM BAX BCL10 BCL11A BCL11B BCL2
5 mortality/aging MP:0010768 9.73 ALK ATM BAX BCL10 BCL11A BCL11B
6 neoplasm MP:0002006 9.23 ALK ATM BAX BCL11B BCL2 CCND1

Drugs & Therapeutics for Lymphoma

FDA approved drugs:

(show all 27)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
2
Arranon 18 49 NELARABINE GlaxoSmithKline October 2005
3
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
4
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Bexxar 18 49 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
6
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
7
Elitek 18 49 RASBURICASE sanofi-aventis October 2009
8
Elliotts B Solution 18 CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE Orphan Medical October 1996
9
Folotyn 18 49 PRALATREXATE Allos Therapeutics September 2009
10
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
11
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
13
Kyprolis 18 49 CARFILZOMIB Onyx Pharmaceuticals July 2012
14
Mozobil 18 49 PLERIXAFOR Genzyme December 2008
15
Neumega 18 OPRELVEKIN Genetics Institute November 1997
16
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
17
Rituxan 18 49 RITUXIMAB Biogen IDEC, Genentech November 1997
18
Targretin 18 49 bexarotene VALEANT LUXEMBOURG 12/29/1999
19
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
20
UVADEX 18 METHOXSALEN Therakos February 1999
21
Valchlor 18 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
22
Velcade 18 49 BORTEZOMIB Millennium Pharmaceuticals May 2003
23
Xalkori 18 49 CRIZOTINIB Pfizer August of 2011
24
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
25
Zydelig 18 49 IDELALISIB Gilead July 2014
26
Zykadia 18 49 CERITINIB Novartis April 2014
27
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 990)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
3
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
8
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
9
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-22-7, 2068-78-2 5978
11
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 95058-81-4 60750
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
14
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
15
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-05-2, 1959-05-2 126941
16
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
17
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
18
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
19
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
20
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 11953898 44475014
21
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
22
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
23
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
24
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
25
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
26
Fosaprepitant Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 172673-20-0 219090
27
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 6918365 151165
28
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
29
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
30
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
31
Tropisetron Approved, Investigational Phase 4,Not Applicable 89565-68-4, 105826-92-4 5595
32
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
33
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
34
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
35
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
36
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
37
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 65271-80-9 4212
38
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
39
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
41
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
42
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59917-39-4, 53643-48-4 40839
43
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
44
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
45
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
46
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
47
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
48
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 159351-69-6 6442177
49
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
50
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 6814)
# Name Status NCT ID Phase Drugs
1 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
2 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
3 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
4 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
5 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
6 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
7 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
8 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
9 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
10 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
11 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
12 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
13 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
14 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
15 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
16 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
17 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
18 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
19 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
20 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
21 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Unknown status NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
22 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
23 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
26 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
28 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
29 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
30 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
31 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
32 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
33 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
34 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
35 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
36 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
37 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
38 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
39 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
40 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
41 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
42 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
43 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
44 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
45 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
46 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
47 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
48 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
49 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
50 Prevention of CHOP-induced Chronic Cardiotoxicity Completed NCT00162955 Phase 4 Valsartan

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: lymphoma

Genetic Tests for Lymphoma

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 29

Anatomical Context for Lymphoma

MalaCards organs/tissues related to Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Lung, Thyroid

Publications for Lymphoma

Articles related to Lymphoma:

(show top 50) (show all 33932)
# Title Authors Year
1
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. ( 30276438 )
2019
2
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. ( 30546948 )
2019
3
Intraocular involvement is associated with a high risk of disease relapse in primary central nervous system lymphoma. ( 30320386 )
2019
4
Plasma fibrinogen level as possible prognostic biomarker in diffuse large B-cell lymphoma. ( 30198830 )
2019
5
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma. ( 30101679 )
2019
6
Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. ( 30141066 )
2019
7
Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone. ( 30083824 )
2019
8
Aneurysmal dilation of bowel mimicking an abscess in pediatric primary gastrointestinal lymphoma. ( 30338011 )
2019
9
Intravascular large B-cell lymphoma presenting with diffusely increased pulmonary fluorodeoxyglucose uptake without corresponding CT abnormality. ( 30510608 )
2019
10
Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis. ( 30479190 )
2019
11
Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. ( 30394941 )
2019
12
Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified. ( 30430783 )
2019
13
Cutaneous B-Cell Lymphoma. ( 30497672 )
2019
14
miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway. ( 30365139 )
2019
15
Methotrexate (MTX)-associated malignant lymphoma of the bilateral breast: imaging features in comparison to other nipple-areolar tumors. ( 30340074 )
2019
16
Canine and Feline Cutaneous Epitheliotropic Lymphoma and Cutaneous Lymphocytosis. ( 30262145 )
2019
17
A role for surgery in the treatment of relapsed Hodgkin lymphoma. ( 30294914 )
2019
18
Primary diffuse large B-cell non-Hodgkin's lymphoma of the breast-A case report and review of the literature. ( 30305860 )
2019
19
FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. ( 30219963 )
2019
20
Orbital lymphoma. ( 30144455 )
2019
21
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
22
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma. ( 29805746 )
2018
23
MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma. ( 29559342 )
2018
24
A Rare Manifestation of Primary Bone Lymphoma: Solitary Diffuse Large B-Cell Lymphoma of the Little Finger. ( 29398333 )
2018
25
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. ( 29416618 )
2018
26
Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. ( 29442161 )
2018
27
Plasmablastic lymphoma presenting as a ureteral polypoid mass. ( 29692511 )
2018
28
Intestinal Perforation Due to Crohn's Ileitis Immunosuppression Related Lymphoma and Meckel's Diverticulum. ( 29730434 )
2018
29
Management of radiation-induced valvular heart disease due to Hodgkin's Lymphoma in the modern era. ( 29131805 )
2018
30
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway. ( 29923173 )
2018
31
A Case of Extranodal Metastasis of Primary Bone Lymphoma in the Lower Extremity. ( 29547041 )
2018
32
Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. ( 29674443 )
2018
33
An unusual presentation of primary pulmonary extranodal marginal zone lymphoma of mucosal associated lymphoid tissue: An autopsy case report. ( 29452080 )
2018
34
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials. ( 29978458 )
2018
35
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
36
Radiation therapy in primary testicular lymphoma: does practice match the standard of care? ( 29966467 )
2018
37
Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) presenting as an endobronchial lesion: Case report and literature review. ( 29719812 )
2018
38
Indolent, waxing and waning cutaneous presentation of HTLV-1-associated adult T-cell leukemia/lymphoma in an HIV-1-positive patient. ( 29094771 )
2018
39
Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation. ( 29463854 )
2018
40
Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-I^t in peripheral T-cell lymphoma, not otherwise specified. ( 29775622 )
2018
41
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. ( 29774105 )
2018
42
Adult-onset hydroa vacciniforme-like lymphoma in a long-term resident of the United States. ( 29693057 )
2018
43
T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. ( 29845599 )
2018
44
Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) and all-trans retinoic acid (ATRA). ( 29963527 )
2018
45
Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for RHOA mutation detection in angioimmunoblastic T-cell lymphoma. ( 29493850 )
2018
46
Primary Cutaneous Follicle Center Lymphoma Clear Cell Variant: Expanding the Spectrum of Cutaneous Clear Cell Neoplasms. ( 29877892 )
2018
47
Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. ( 29978498 )
2018
48
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. ( 29679112 )
2018
49
Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ( 29390098 )
2018
50
Epstein-Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma. ( 28744882 )
2018